Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.58 |
| ▸ | F7 | P08709 | 1/20 | 0.55 |
| ▸ | F3 | P13726 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 5/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.46 |
| ▸ | TUBB | P07437 | 1/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.46 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.46 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16136470 | 0.83 | GPR84 (0.58) | GPR84F7F3HTR2ATRPM8 | |
| Ethoxycarbonyl Group SCHEMBL27448995 | 0.81 | GPR84 (0.44) | GPR84F7F3HTR2ATRPM8 | |
| SCHEMBL28207416 | 0.78 | GPR84 (0.62) | GPR84HTR2ATRPM8NR4A2IDO1 | |
| SCHEMBL38663621 | 0.78 | GPR84 (0.62) | GPR84F7F3HTR2ATRPM8 | |
| SCHEMBL5434525 | 0.77 | GPR84 (0.51) | GPR84F7F3HTR2ATRPM8 | |
| SCHEMBL20846141 | 0.77 | MEN1 (0.48) | GPR84F7F3HTR2ATRPM8 | |
| SCHEMBL17439076 | 0.75 | F7 (0.59) | GPR84F7F3HTR2ATRPM8 | |
| SCHEMBL5197534 | 0.75 | HTR2C (0.53) | HTR2ASLC6A4 | |
| SCHEMBL14149493 | 0.75 | HTR1D (0.51) | HTR2ANR4A2IDO1TUBB4ATUBB | |
| SCHEMBL17982265 | 0.75 | GPR84 (0.58) | GPR84F7F3HTR2ATRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9761813-B2 | Organic light-emitting compound and organic electroluminescent device using same | DOOSAN CORPORATION (KR) | 2017-09-12 | — | — | US | disclosed |
| US-9761813-B2 | Organic light-emitting compound and organic electroluminescent device using same | DOOSAN CORPORATION (KR) | 2017-09-12 | — | — | US | disclosed |
| US-20150214490-A1 | ORGANIC LIGHT-EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | DOOSAN CORPORATION (KR) | 2015-07-30 | — | — | US | disclosed |
| US-20150214490-A1 | ORGANIC LIGHT-EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | DOOSAN CORPORATION (KR) | 2015-07-30 | — | — | US | disclosed |
| CN-104736537-A | Organic light-emitting compound and organic electroluminescent device using same | DOOSAN CORP | 2015-06-24 | — | — | CN | disclosed |
| US-RE45173-E1 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| EP-2445903-B1 | 1,3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| WO-2014025114-A1 | ORGANIC LIGHT-EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | 주식회사 두산 (KR) | 2014-02-13 | — | — | WO | disclosed |
| CN-102803250-A | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP17 | NOVARTIS AG | 2012-11-28 | — | — | CN | disclosed |
| US-8263635-B2 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331326-A1 | Inhibitors of CYP 17 | CYP17A1, CYP21A2, CYP4A22 | GPR84 1967/4885F7 2819/4885F3 1132/4885 |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | CYP17A1, CYP21A2, CYP4A22 | GPR84 1967/4885F7 2819/4885F3 1132/4885 |
| US-20150214490-A1 | ORGANIC LIGHT-EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | IDO1, IDO2, KYNU | GPR84 2418/4885F7 3944/4885F3 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.